Pre Diagnostics AS   Report issue

For profit Phase 2
Founded: Oslo Norway (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2018
NCT03926351
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Pre Diagnostics AS

Active Ingredients

Drugs in Phase 2 Trials (2)

olive (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Central Nervous System Diseases (Phase 2)

Cognition Disorders (Phase 2)

Cognitive Dysfunction (Phase 2)

Dementia (Phase 2)

Disease (Phase 2)

Inflammation (Phase 2)

Mental Disorders (Phase 2)

Nervous System Diseases (Phase 2)

Neurocognitive Disorders (Phase 2)

Pathologic Processes (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2